Clinical

Articles

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.

Results Show Promising Efficacy in MCL With Next-Generation BTK Inhibitor LOXO-305

Videos

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCL

Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.

Laurie H. Sehn, MD, on the Impact of Additional Findings From the GO29365 Study in DLBCL

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

Quality of Life Improves Over Time for Patients With Aggressive Lymphomas

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

MEDI-570 Evokes Durable Reponses in Patients with R/R T-Cell Lymphomas

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

Christian Buske, MD, on the Influence of CAR T-Cells Being Presented at ASH

The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

Axi-Cel Induces Long-Term Disease Control in Large B-Cell Lymphoma

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

Axicabtagene Ciloleucel Demonstrates Improved ORR in Indolent Non-Hodgkin Lymphoma

A study presented at ASTRO suggested that response-based consolidation involved-field radiation therapy appears to be a safe and effective standard of care for a cohort of pediatric patients with high-risk classical Hodgkin lymphoma.

Lymphoma | Topics